Archive | Press Releases

RSS feed for this section

Daxor Corporation Announces Death of Founder, Chief Medical Officer, and Developer of Blood Volume Analysis and Inventor the Daxor BVA-100 Device, Dr. Joseph Feldschuh

New York, NY February 1, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, sadly announced today the death of the Company’s founder and its first President and Chief Executive Officer, Dr. Joseph Feldschuh. Dr Feldschuh, who was working on a part-time basis and responding well treatment for […]

Daxor Corporation Announces Dividend, Patent Approval, Title Change

New York, NY, November 18, 2016 – Daxor Corporation, an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend for 2016. The Board of Directors has unanimously approved an annual dividend payment of $0.03 per share. This dividend will be paid on Thursday, December 29, 2016 to Daxor shareholders of […]

Two New Studies from the Mayo Clinic and Lankenau Medical Center Presented at Heart Failure Society of America 2016 Highlight Unique Ability of BVA to Identify High Risk at Discharge in Hospitalized Heart Failure Patients

New York, NY September 29, 2016 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces two new studies presented at the Heart Failure Society of America meeting this month highlighting risks for hospitalized heart failure patients detectable by direct blood volume measurement (Daxor BVA-100). Michael Feldschuh, President and […]

Daxor Corporation Announces Filing of Form N-CSR for June 30, 2016

New York, NY September 15, 2016 – Marketwired – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed its Form N-CSR on Tuesday, August 30, 2016 disclosing its schedule of portfolio holdings as of June 30, 2016. Copies of the form will be mailed to the Company’s shareholders and […]

Daxor Corporation Announces Hiring of Chief Financial Officer

New York, NY June 17, 2016 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces the hiring of Eric P. Coleman as its new Chief Financial Officer effective June 6, 2016, reporting directly to Michael Feldschuh, Acting President & CEO of Daxor Corporation. “Mr. Coleman will be responsible […]

Real­World Impact on Heart Failure Mortality and Readmissions of Individualized Care Guided by Blood Volume Analysis: New Data Presented at the American College of Cardiology Congress

  New York, NY April 6, 2016 ­ Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces the first interventional outcomes data to be presented in heart failure patients receiving individualized care guided by direct blood volume analysis (BVA). The data were presented at the American College of Cardiology congress by John […]

University of Hawaii and The Queens’s Hospital Reports on a Study on Critically Ill Patients Utilizing Blood Volume Measurement and Pulmonary Artery Catheterization

New York, NY March 9, 2016 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces a study on critically ill patients utilizing blood volume measurement and pulmonary artery catheterization (PAC). Pulmonary artery catheterization, an invasive procedure, involves threading a catheter into the heart to measure pressures. Millions of […]

Daxor Corporation Announces Upcoming Filing of Form N-CSR for December 31, 2015 and Recent Developments

NEW YORK, NY–(Marketwired – Feb 29, 2016) – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, expects to be filing a Form N-CSR within the next week disclosing its schedule of portfolio holdings as of December 31, 2015. Copies of the form will be mailed to the Company’s shareholders and will be […]

Daxor Corporation Announces Return of Dr. Joseph Feldschuh After Pancreatic Cancer Surgery

  Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announces Dr. Joseph Feldschuh, CEO of Daxor, Returns to Work After Medical Leave On December 14, 2015 Dr. Feldschuh undertook a medical leave of absence. At that time the Board of Directors of Daxor appointed Michael Feldschuh, previously the Executive […]

Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as President and Chief Executive Officer on a Temporary Basis

Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as President and Chief Executive Officer on a Temporary Basis Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend today along with the appointment of Michael Feldschuh, currently Executive Vice President, as […]